No abstract available
Keywords:
down syndrome; neonatal leukaemia; transient abnormal myelopoiesis; transient leukaemia; transient myeloproliferative disorder.
Publication types
-
Practice Guideline
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antimetabolites, Antineoplastic / therapeutic use
-
Blood Cell Count
-
Cell Transformation, Neoplastic
-
Critical Illness
-
Cytarabine / therapeutic use
-
DNA Mutational Analysis / methods
-
Down Syndrome / pathology
-
Down Syndrome / therapy*
-
Exchange Transfusion, Whole Blood / methods
-
Female
-
Fetal Diseases / diagnosis
-
GATA1 Transcription Factor / genetics
-
Humans
-
Leukapheresis / methods
-
Leukemoid Reaction / pathology
-
Leukemoid Reaction / therapy*
-
Liver Diseases / therapy
-
Mutation / genetics
-
Neoplasm, Residual / diagnosis
-
Pregnancy
-
Prenatal Diagnosis / methods
-
Prognosis
-
Recurrence
-
Risk Factors
Substances
-
Antimetabolites, Antineoplastic
-
GATA1 Transcription Factor
-
GATA1 protein, human
-
Cytarabine
Supplementary concepts
-
Myeloproliferative Syndrome, Transient